Jupiter Topco LLC Acquires New Stake in Omeros Corporation $OMER

Jupiter Topco LLC bought a new stake in Omeros Corporation (NASDAQ:OMER) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,500 shares of the biopharmaceutical company’s stock, valued at approximately $290,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of OMER. BlackRock Inc. bought a new position in Omeros during the second quarter worth $57,484,000. Vanguard Group Inc. lifted its position in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after buying an additional 666,357 shares during the last quarter. Corient Private Wealth LLC grew its position in shares of Omeros by 13.0% during the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after buying an additional 79,263 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Omeros by 57.8% during the first quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company’s stock valued at $2,163,000 after purchasing an additional 74,997 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Omeros in the second quarter worth $1,864,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on OMER shares. HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Cantor Fitzgerald upgraded Omeros from a “neutral” rating to an “overweight” rating and set a $22.00 target price on the stock in a research report on Tuesday, September 22nd. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings cut Omeros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Omeros Price Performance

Shares of OMER stock traded down $0.05 on Tuesday, hitting $19.38. The company’s stock had a trading volume of 392,591 shares, compared to its average volume of 1,687,282. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of 15.14 and a beta of 2.60. Omeros Corporation has a fifty-two week low of $4.05 and a fifty-two week high of $21.24. The firm’s fifty day moving average price is $16.40 and its 200-day moving average price is $13.11.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Arnold Hanish sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the transaction, the director owned 5,000 shares in the company, valued at approximately $94,750. The trade was a 66.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO David Borges sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the transaction, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at $104,750. This represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,906 shares of company stock worth $1,989,705 in the last 90 days. 10.50% of the stock is owned by company insiders.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.